

Algorithm, Clinical Highlights, Annotations

Algorithm:

- Algorithm boxes #12, #14, #25 and #27 have been clarified and now include the word “ago” after days, e.g. TIA symptoms >7 days ago.
- Algorithm boxes #12 and #25 now include the same language.
- *Algorithm box #24 has been revised and now includes lab tests listed in the Annotation.
- *Algorithm box #24 now includes lipids, Hgb A1c, and fasting glucose. Risk factors assessment has also been included.

Annotations:

- Annotation #18: The ECASS III statement was re-written.
- *Annotation #21: Revision made to “Laboratory tests.” The tests are as follows: complete blood count, lipids, electrolytes, glucose, BUN, creatinine, Cardiac biomarkers, INR, activated partial thromboplastin time.
- Annotation #21: “7-day risk of stroke” removed from table. “Risk of stroke at two days” removed from table.
- Annotation #24: Incorporated telemetry and ICU as clarifications to monitored unit.
- *Annotation #24: Revision made to “Laboratory tests. The tests are as follows: complete blood count, fasting lipid profile, fasting glucose, serial cardiac biomarkers if suspect acute coronary syndrome, consider Hgb A1c if suspect diabetes, monitoring, echocardiogram.
- *Annotation #26: Revision made to “Laboratory tests.” The tests are as follows: complete blood count, glucose, electrolytes, BUN Sedimentation rate (ESR), creatinine, fasting lipid profile, fasting glucose, consider Hgb A1c if suspect diabetes.
- Annotation #30: The third bullet has been removed. Age has been incorporated into the first bullet. Removed bullet 4 and 5 under “Key Points”.
- Annotation #30: Moved “Criteria for consideration of angiographic evaluation for intra-arterial treatment” under “Basilar artery occlusion defined by the following.”
- Annotation #30: The section “Basilar artery occlusion” has been deleted.
- *Annotation #35: Oral administration has been added along with an expanded discussion of the swallow evaluation in Annotation #38.
- *The verbiage, “within a three hour window (4.5 hours in select patients)” has been added consistently throughout the guideline where appropriate.
- Annotation #35: Three paragraphs beginning with, “On September 8, 2009...” have been deleted.

- Annotation #35: The first paragraph under “Heparin use for VTE prophylaxis” has been deleted.
- Annotation #38: A more robust statement has been added to “Perform Swallow Evaluation.”

Appendix:

- Appendix B has been added to the guideline. The topic of this new appendix is, Acute Stroke Care Networks.
- Appendix D has been added to the guideline, “Stroke Dysphagia Screen.”

Priority Aims & Suggested Measures, Measurement Specifications

- A measurement specification has been added around Aims #5, Measurement “f.”

References added

ATLANTIS 2004
 Adams 2005
 Clark 1999
 Del Zappo 2009
 Frey 2005
 Hacke 2008, 2004
 Hoody 2008
 Meyer 2008
 Odderson 1995
 Perry 2001
 Rymer 2003
 Schwamm 2009
 Silliman 2003
 Silverman 2005
 Switzer 2008, 2009
 Vaishnav 2008
 Wang, 2000, 2003, 2004
 Charipar 2008

**An asterisk indicates any changes in clinical practice recommendations*